Biocon Corporate Presentation
The Biocon Journey: A Continuous Evolution
1978-
1999
2000-
2004
2005-
2009
2010-
2016-
2015
2018
2019 &
Beyond
Transforming into
An Enzymes
Company
a Biopharma
Company
Successful IPO,
Biocon listed in
India (2004)
Building the Base
Business and
Expertise in
Biologics
Enzymes Business
Divested (2007)
Global Development
of Biosimilars in
Partnership with
Mylan (2009)
Strategic Global
Alliance with Mylan
for Biosimilars
Expanded (2013)
Generic
Formulations
Business Unit set up
(2013)
IPO of Syngene
(2015)
Commercialized
Biosimilars for
Diabetes & Cancer
in Japan, U.S., EU
Global Partnership
with Sandoz for
Next-Gen
Biosimilars (2018)
Poised for
Global Impact
with
Biosimilars
Investments in
complex
Generic
Formulations
Unwavering focus through the years on innovation & difficult to make, niche products to
create tangible differentiators for sustainable growth
ā Biocon
5
LOView entire presentation